Dark

Check out our Level2View

ACUR
ACURA PHARMS INC
stock OTC

EOD

Jul 1, 2025

0.000200USD-92.000%(-0.002300)36,000

Pre-market

0.00USD-100.000%(0.00)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Dec 14, 2021

09:35AM EST Acura Pharmaceuticals Granted U.S. Patent #11,197,837 'Methods and compositions for interfering with extraction or conversion of a drug susceptible to abuse' Benzinga

Aug 16, 2021

04:15PM EDT Acura Pharmaceuticals, Inc. (OTCQB: ACUR), an innovative drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications, announced today financial results for the three and six months ended June 30, 2021. GlobeNewswire Inc

Jul 26, 2021

04:15PM EDT Acura Pharmaceuticals, Inc. (OTCQB: ACUR) today announced an amendment to its License, Development and Commercialization Agreement (Agreement) regarding Acuras LIMITx LTX-03 product candidate with Abuse Deterrent Pharma, LLC (AD Pharma) to extend the FDA Acceptance Date for LTX-03 (NDA Acceptance Date) to February 28, 2022. GlobeNewswire Inc

Jun 14, 2021

04:10PM EDT Acura Pharmaceuticals Announces Conversion of Debt GlobeNewswire Inc

Jun 7, 2021

06:07AM EDT Acura Pharma Completes 3 NDA Required Registration Batches Of To-be-marketed LTX-03 Formulation RTTNews

06:00AM EDT Acura Pharmaceuticals Provides Development Update on LTX-03 GlobeNewswire Inc

May 17, 2021

04:15PM EDT Acura Pharmaceuticals, Inc. (OTCQB: ACUR), an innovative drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications, announced today financial results for its first quarter ended March 31, 2021. GlobeNewswire Inc

Mar 31, 2021

04:15PM EDT Acura Pharmaceuticals, Inc. (OTCQB: ACUR), an innovative drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications, announced today financial results for the three and twelve months ended December 31, 2020. GlobeNewswire Inc

Nov 16, 2020

04:17PM EST Acura Pharmaceuticals, Inc. (OTCQB: ACUR), a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and product candidates intended to mitigate the risk of outcomes associated with product misuse, announced today financial results for the three and nine months ended September 30, 2020. GlobeNewswire Inc

Aug 14, 2020

06:00AM EDT Acura Pharmaceuticals, Inc. (OTCQB: ACUR), a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and product candidates intended to mitigate the risk of outcomes associated with product misuse, announced today financial results for the three and six months ended June 30, 2020. GlobeNewswire Inc

Share